chemotherapy + cemiplimab + alirocumab

chemotherapy + cemiplimab + alirocumab is an experimental neoadjuvant combination therapy being evaluated in the TOP 2301 phase 2 clinical trial at Duke University for the treatment of stage 1B-3A non-small cell lung cancer (NSCLC). The regimen combines standard-of-care platinum-based chemotherapy with cemiplimab (Libtayo), a monoclonal antibody targeting the PD-1 receptor to enhance anti-tumor immune responses, and alirocumab (Praluent), a monoclonal antibody targeting PCSK9. While alirocumab is traditionally used for cholesterol management, preclinical evidence suggests that PCSK9 inhibition can prevent the degradation of MHC-I on tumor cells, thereby increasing their susceptibility to cytotoxic T-cell mediated death and potentially overcoming resistance to PD-1/PD-L1 checkpoint inhibitors.

Other names

chemotherapy-Duke University-non-small cell lung cancerneoadjuvant chemotherapy and cemiplimab with or without alirocumabchemotherapy + cemiplimab +/- alirocumab